Stocktoria
PLIANT THERAPEUTICS, INC. PLRX
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2020-06-03
PLIANT THERAPEUTICS, INC. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.6M | $9.7M | $7.6M |
| R&D expense | $109.2M | $169.3M | $127.8M | $96.9M | $77.5M |
| Operating income | -$156.4M | -$228.4M | -$184.1M | -$127.2M | -$97.5M |
| Interest expense | — | — | $1.3M | $791,000 | $0 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$149.3M | -$210.3M | -$161.3M | -$123.3M | -$97.3M |
| EPS (diluted) | $-2.43 | $-3.47 | $-2.75 | $-2.94 | $-2.71 |
| Operating cash flow | -$128.3M | -$155.5M | -$116.4M | -$94.6M | -$75.4M |
| Free cash flow | -$128.7M | -$159.4M | -$117.3M | -$96.4M | -$77.4M |
| Cash & equivalents | $45.4M | $71.2M | $63.2M | $33.7M | $51.7M |
| Total assets | $225.2M | $396.9M | $512.2M | $350.6M | $221.2M |
| Total liabilities | $44.0M | $92.9M | $38.6M | $37.3M | $22.2M |
| Shareholders' equity | $181.2M | $304.1M | $473.6M | $313.3M | $199.1M |
Source: SEC EDGAR filings · CIK 0001746473 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.